

Metastatic Melanoma Pathways

Patient Name: _____ Date of Birth: _____

Member Number: _____ Treatment Start Date: _____

ICD-10 Code: _____ Pathology: _____

Stage: __0 __IA __IB __IIA __IIB __IIC __III __IV __Recurrent

Line of Treatment: __Adjuvant/Post-Op __First Line __Second Line __Third Line __Third Line +

ECOG Performance Status: __0 __1 __2 __3 __4

Biomarkers:

BRAF* status: __V600E Mutation positive __V600K Mutation positive __Wild Type (no mutation) __Not Reported

c-kit status: __Exon 11 Mutation Present __Exon 9 Mutation Present __No Mutation __Not Reported

Metastatic Disease | First Line (1st line) | ECOG PS: 0, 1, 2 | Any BRAF status

Nivolumab (Opdivo)

Metastatic Disease | First and subsequent lines of therapy (1st line +) | ECOG PS: 0, 1, 2 | BRAF mutation +

Dabrafenib (Tafinlar) and trametinib (Mekinist)

Metastatic Disease | Second and subsequent lines of therapy (2nd line +) | ECOG PS: 0, 1, 2 | Any BRAF status

Ipilimumab (Yervoy)